Cancer therapy developer, Invion (ASX:IVX) has strengthened its scientific advisory board appointing experts in skin, lung and prostate cancer.
New appointees include, Dr Lynda Spelman, Assoicate Professor Louis Irving and Associate Professor Nathan Lawrentschuk.
Invion says the appointments will advance clinical development and help ensure that the Invion drugs and devices are optimized for each cancer type.
The company is developing photodynamic therapies for a range of cancers including skin, ovarian prostate and lung cancer.
Shares in Invion (ASX:IVX) last traded at 6 cents.